State Street Corp Has $15.96 Million Stock Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

State Street Corp increased its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 864.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,911,327 shares of the biopharmaceutical company's stock after buying an additional 1,713,200 shares during the quarter. State Street Corp owned about 3.53% of Emergent BioSolutions worth $15,960,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new stake in shares of Emergent BioSolutions during the 2nd quarter worth $41,000. Verus Capital Partners LLC bought a new stake in shares of Emergent BioSolutions during the 2nd quarter valued at approximately $68,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Emergent BioSolutions during the 2nd quarter valued at approximately $93,000. Stifel Financial Corp acquired a new position in Emergent BioSolutions during the 3rd quarter worth approximately $96,000. Finally, Morse Asset Management Inc bought a new position in Emergent BioSolutions in the 2nd quarter valued at approximately $97,000. Institutional investors own 78.40% of the company's stock.

Emergent BioSolutions Trading Up 1.8 %

EBS traded up $0.15 during trading on Wednesday, reaching $8.30. 536,152 shares of the stock traded hands, compared to its average volume of 3,133,036. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The stock's 50-day moving average is $9.27 and its 200 day moving average is $8.85. Emergent BioSolutions Inc. has a 12 month low of $1.42 and a 12 month high of $15.10. The stock has a market capitalization of $449.73 million, a PE ratio of -2.02 and a beta of 1.59.

Wall Street Analysts Forecast Growth

EBS has been the topic of a number of research reports. Rodman & Renshaw restated a "buy" rating and set a $16.00 price objective on shares of Emergent BioSolutions in a research report on Friday, September 13th. Benchmark boosted their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, StockNews.com lowered shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Friday, December 20th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.